蓝鲸新闻11月2日电,蓝鲸新闻记者在2025年国家医保目录现场谈判与商保创新药目录价格协商现场,从行业人士处获悉,预计今年共20余款药品参与商保创新药目录价格协商,且价格协商时间将从今日下午持续到明日,目前已有约十家药企进入今日下午价格协商会场。其中,百济神州携多款药品入场,包括注射用泽尼达妥单抗、达妥昔单抗β注射液以及注射用贝林妥欧单抗都已过商保创新药目录初审名单,贝林妥欧单抗是商保和医保谈判...
Source Link蓝鲸新闻11月2日电,蓝鲸新闻记者在2025年国家医保目录现场谈判与商保创新药目录价格协商现场,从行业人士处获悉,预计今年共20余款药品参与商保创新药目录价格协商,且价格协商时间将从今日下午持续到明日,目前已有约十家药企进入今日下午价格协商会场。其中,百济神州携多款药品入场,包括注射用泽尼达妥单抗、达妥昔单抗β注射液以及注射用贝林妥欧单抗都已过商保创新药目录初审名单,贝林妥欧单抗是商保和医保谈判...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.